ClinicalTrials.gg
CompletedNCT017435604EVERUKUpdated Jul 18, 2019Results posted

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

A Phase 4 interventional study of RAD001 and Exemestane in Oestrogen Receptor Positive Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.

Enrollment
43rd of 78
52 · median 55
Started
2013
with 10 others
Phase 4
2 of 78
none open now
Registered
38th of 78
by date
Lead sponsor
14 of 78
Novartis Pharmaceuticals

Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 43rd largest by enrollment, is one of 11 that started in 2013, is one of 2 in phase 4, and was the 38th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing everolimus in Breast Neoplasms, or all of them as a file.
02

Study summary

Determine the overall response rate (ORR) at 48 weeks to everolimus (RAD001, 10mg daily p.o.) and exemestane (25mg daily p.o.) treatment in postmenopausal women with oestrogen receptor positive breast cancer who have previous experienced recurrence or progression on non-steroidal aromatase inhibitor (NSAI) therapy.

03

Conditions studied

  • Oestrogen Receptor Positive Advanced Breast Cancer

Keywords

  • Breast Neoplasms
  • Neoplasms
  • Breast diseases
  • Skin diseases
  • Exemestane
  • Antibiotics, Antineoplastic
  • Everolimus
  • Antineoplastic Agents
  • Therapeutic Uses
  • Pharmacologic Actions
  • Immunosuppressive Agents
  • Physiological Effects of Drugs
  • Aromatase Inhibitors
  • Enzyme Inhibitors
  • Molecular Mechanisms of Pharmacological Action
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological confirmation of oestrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+), human epidermal growth factor receptor 2 () negative breast cancer.
  • Availability of (the tissue block or slides will be sent to the central laboratory for analysis).
  • women. The investigator must confirm postmenopausal status. Postmenopausal status is defined either by:

    • Age ≥ 55 years and one year or more of amenorrhea
    • Age \< 55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH per local institutional standards
    • Prior hysterectomy and has postmenopausal levels of Follicle stimulating hormone (FSH) and Luteinizing Hormone (LH) per local institutional standards Surgical menopause with bilateral oophorectomy
  • Disease progression following prior therapy with NSAI, defined as:

    • Recurrence while on or after completion of an treatment including letrozole or anastrozole, or
    • Progression while on or following the completion of letrozole or anastrozole treatment for locally advanced or breast cancer

Note: Non-steroidal aromatase inhibitors (i.e. letrozole or anastrozole) do not have to be the last treatment prior to enrollment. Other prior anticancer therapy, e.g. tamoxifen, fulvestrant, exemestane are also allowed. Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to enrollment.

  • Radiological evidence of recurrence or progression on last systemic therapy prior to enrollment.

Patients must have:

  • At least one lesion that can be accurately measured or
  • Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of

    • Adequate bone marrow and coagulation function as shown by:
  • (ANC) ≥ 1.5 109/L
  • ≥ 100 ×109/L
  • (Hb) ≥ 9.0 g/dL
  • (INR) ≤ 2 .

    • Adequate liver function as shown by:
  • Serum (AST) and alanine aminotransferase (ALT) ≤ 2.5 (or ≤ 5 if hepatic metastases are present)
  • Total serum ≤ 1.5 × ULN (≤ 3 × ULN for patients known to have Gilbert Syndrome)

    • Adequate renal function as shown by:
  • Serum creatinine ≤ 1.5 × ULN

    • Fasting serum cholesterol ≤ 300 mg/dl or 7.75 mmol/L and fasting triglycerides ≤ 2.5 × ULN. In case one or both of these thresholds are exceeded, the patient can only be included after initiation of statin therapy and when the above mentioned values have been achieved
    • (ECOG) performance status of PS \</ 2
    • Written obtained before any screening procedure and according to local guidelines.

Exclusion criteria

Exclusion Criteria:

  • -overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).
  • Pre-menopausal, pregnant, lactating women.
  • Known to mammilian target of Rapamycin (mTOR) inhibitors, e.g. sirolimus (rapamycin) or to their .
  • Known hypersensitivity to exemestane, to the active substance or to any of the excipients.
  • Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption.
  • Radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within two weeks prior to enrollment. Patients must have recovered from radiotherapy toxicities prior to enrollment.
  • Currently receiving hormone replacement therapy, unless discontinued prior to enrollment.
  • Patients receiving concomitant agents or chronic use, at the time of study entry except in cases outlined below:

Prolonged systemic corticosteroid treatment during study, except for topical applications (e.g. rash),inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) should not be given. However:

  • short duration (\<2 weeks) of systemic corticosteroids is allowed (e.g. , anti-emetic)
  • low doses of corticosteroids for treatment is allowed
  • Patients with symptomatic visceral (e.g. significant dyspnoea related to pulmonary lymphangitic carcinomatosis and lung metastases or symptomatic liver metastasis)
  • Symptomatic brain or other Central Nervous system (CNS) metastases.
  • Active, bleeding diathesis, or on oral anti-vitamin K medication (except low dose warfarin, low molecular weight heparin (LMWH) and acetylsalicylic acid or equivalent, as long as the is 2.0)
  • Any severe and / or uncontrolled medical conditions such as:

    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to enrollment, serious uncontrolled cardiac arrhythmia
    • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 ×
    • Acute and chronic, active infectious disorders (except for Hep B and Hep C positive patients) and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome)
    • Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary function tests including measures of predicted lung volumes, DLco, O2 saturation at rest on room air should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltrates.
  • Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme (rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, telithromycin) within the last 5 days prior to enrollment
  • History of non-compliance to medical regimens
  • Patients unwilling to or unable to comply with the protocol
  • Another within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Everolimus and Exemestane

    Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.

    Drug: RAD001 · Drug: Exemestane

Interventions

  • DrugRAD001

    All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.

    Also known as: Everolimus

  • All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

    The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.

    Time frame: At 48 weeks

  2. Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

    The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Treatment success is defined as: The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.

    Time frame: At 48 weeks

Secondary outcomes

  1. Progression-free Survival (PFS) Events as Per Investigators - FAS

    Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.

    Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks

  2. Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS

    Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.

    Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks

  3. Progression-free Survival (PFS) - % Event-free Probability Estimate - FAS

    Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review. The PFS was analyzed using the Kaplan Meier method.

    Time frame: Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks

  4. Overall Survival (OS) Events (Number of Deaths) - FAS

    Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Time to median OS was not estimable.

    Time frame: Start of treatment to the date of death up to approximately 48 weeks

  5. Overall Survival (OS) - % Event-free Probability Estimate - FAS

    Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.

    Time frame: Start of treatment to the date of death up to approximately 48 weeks

  6. Change From Baseline EORTC Quality of Life Questionnaire of Cancer Patients QLQ-C30 at Each Time Point

    The QLQ-C30 is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations

    Time frame: Baseline 12,24,36,48 weeks

  7. Percentage of Patient Responses in EuroQoL 5-dimension Questionnaire - FAS

    EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D descriptive system is comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Percentage of participants' responses were presented by visits. Results should be interpreted with caution as the numbers of patients with available data over time were limited.

    Time frame: Baseline 12,24,36,48 weeks

  8. Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS

    EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). For the visual analogue scale, participants draw a line from a box to the point on the thermometer-like scale corresponding to their health state, 0-100 (100 = Best health state). Weights are used to score the responses to the 5 domains, with scores ranging from 0 to 1 (where a score of 1 represents a perfect state). Scores for the visual analogue scale reflect the position where participant's line crosses the thermometer-like scale. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations

    Time frame: Baseline 12,24,36,48 weeks

07

Results

Posted Apr 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneEverolimus and Exemestane
Started52
Full analysis set (fas)49
Safety analysis set (saf)49
Completed9
Not completed43
Withdrew: Disease progression26
Withdrew: Adverse event8
Withdrew: Death3
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation1
Withdrew: >1 dose of study drug3

Outcome measures

PrimaryBest Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48.

Time frame:
At 48 weeks
Reported as:
Number · participants
Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
participantsEverolimus and Exemestane
Patients with measurable disease at baseline39
Patients with non-measurable disease at baseline10
Best at WK 48 - Complete Response (CR)0
Best at WK 48 - Partial Response (PR)7
Best at WK 48 - Stable Disease (SD)18
Best at WK 48 - Progressive Disease (PD)15
Unknown1
Missing8
PrimaryOverall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48. Treatment success is defined as: The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.

Time frame:
At 48 weeks
Reported as:
Number · Percentage of participants
Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Percentage of participantsEverolimus and Exemestane
Overall Response Rate of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer14.3 (6.0 to 27.0)
SecondaryProgression-free Survival (PFS) Events as Per Investigators - FAS

Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.

Time frame:
Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Reported as:
Number · Number of events
Progression-free Survival (PFS) Events as Per Investigators - FAS
Number of eventsEverolimus and Exemestane
Deaths8 (12.71 to 34.29)
Progression of disease25
Number of censored observations16
SecondaryProgression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS

Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review.

Time frame:
Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Reported as:
Median · weeks
Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS
weeksEverolimus and Exemestane
Progression-free Survival (PFS) by Median Time in Weeks as Per Investigators - FAS23.6 (12.71 to 34.29)
SecondaryProgression-free Survival (PFS) - % Event-free Probability Estimate - FAS

Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Tumor assessment and response was evaluated according to RECIST v1.1Response was assessed by local radiology review. The PFS was analyzed using the Kaplan Meier method.

Time frame:
Start of treatment to the date of event defined as first documented progression due to any cause up to approximately 48 weeks
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) - % Event-free Probability Estimate - FAS
Percentage of participantsEverolimus and Exemestane
Event free at 12 weeks67.9 (51.82 to 79.56)
Event free at 24 weeks49.1 (32.98 to 63.44)
Event free at 36 weeks28.9 (15.42 to 43.87)
Event free at 48 weeks18.4 (7.38 to 33.19)
SecondaryOverall Survival (OS) Events (Number of Deaths) - FAS

Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Time to median OS was not estimable.

Time frame:
Start of treatment to the date of death up to approximately 48 weeks
Reported as:
Number · Number of events
Overall Survival (OS) Events (Number of Deaths) - FAS
Number of eventsEverolimus and Exemestane
Deaths8 (12.71 to 34.29)
Number of censored observations41
SecondaryOverall Survival (OS) - % Event-free Probability Estimate - FAS

Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.

Time frame:
Start of treatment to the date of death up to approximately 48 weeks
Reported as:
Number · Percentage of participants
Overall Survival (OS) - % Event-free Probability Estimate - FAS
Percentage of participantsEverolimus and Exemestane
Event free at 12 weeks93.3 (80.57 to 97.78)
Event free at 24 weeks83.9 (66.92 to 92.60)
Event free at 36 weeks74.2 (53.02 to 86.88)
Event free at 48 weeks74.2 (53.02 to 86.88)
SecondaryChange From Baseline EORTC Quality of Life Questionnaire of Cancer Patients QLQ-C30 at Each Time Point

The QLQ-C30 is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations

Time frame:
Baseline 12,24,36,48 weeks
Reported as:
Mean · scores
Change From Baseline EORTC Quality of Life Questionnaire of Cancer Patients QLQ-C30 at Each Time Point
scoresWeek 12Week 24Week 36Week 48
Global health status/QoL-9.0 ± 22.04-3.6 ± 19.711.9 ± 16.37-8.3 ± 22.48
Physical functioning-5.1 ± 19.16-1.0 ± 14.524.9 ± 13.79-10.8 ± 29.97
Role functioning-4.5 ± 33.193.1 ± 23.748.3 ± 23.03-12.3 ± 30.52
Emotional functioning2.6 ± 21.36-3.1 ± 14.877.5 ± 9.900.6 ± 21.59
Cognitive functioning-8.6 ± 21.37-5.2 ± 17.971.3 ± 22.01-3.7 ± 21.35
Social functioning-9.9 ± 25.00-9.4 ± 24.323.8 ± 15.45-14.7 ± 31.74
Fatigue8.6 ± 26.929.5 ± 15.930.9 ± 16.647.3 ± 24.66
Nausea/ vomiting-1.2 ± 15.962.9 ± 16.91-3.8 ± 15.45-2.4 ± 23.88
Pain1.2 ± 26.123.9 ± 24.67-1.3 ± 20.930.6 ± 24.64
Dyspnea18.5 ± 37.368.3 ± 25.822.6 ± 25.3210.7 ± 27.30
Insomnia3.7 ± 26.692.0 ± 29.980 ± 23.57-3.6 ± 37.78
Appetite loss30.9 ± 40.2223.5 ± 28.3012.8 ± 28.9916.7 ± 35.72
Constipation4.9 ± 32.9511.8 ± 28.7310.3 ± 21.018.3 ± 19.51
Diarrhea4.9 ± 25.668.3 ± 37.52-5.1 ± 22.967.4 ± 28.24
Financial problems-1.2 ± 21.64-10.4 ± 26.44-10.3 ± 21.01-2.6 ± 18.67
SecondaryPercentage of Patient Responses in EuroQoL 5-dimension Questionnaire - FAS

EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The EQ-5D descriptive system is comprised of the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Percentage of participants' responses were presented by visits. Results should be interpreted with caution as the numbers of patients with available data over time were limited.

Time frame:
Baseline 12,24,36,48 weeks
Reported as:
Number · Percentage of participants
Percentage of Patient Responses in EuroQoL 5-dimension Questionnaire - FAS
Percentage of participantsDay 1Week 12Week 24Week 36Week 48
Mobility-no problem38.820.418.414.316.3
Mobility-slight problem18.414.310.28.216.3
Mobility-moderate problem32.720.48.22.014.3
Mobility-severe problem6.12.002.06.1
Mobility-unable to walk00004.1
Self-care - no problem69.444.934.724.540.8
Self-care - slight problem18.44.10010.2
Self-care - moderate problem6.18.22.02.04.1
Self-care -severe problem2.00002.0
Self-care - unable00000
Usual activities - no problems30.614.322.414.318.4
Usual activities - slight problems22.416.32.08.214.3
Usual activities - moderate problems28.622.412.22.012.2
Usual activities - severe problems10.24.102.06.1
Usual activities -unable to do4.10006.1
Pain/discomfort - none20.414.310.212.218.4
Pain/discomfort - slight30.616.318.48.220.4
Pain/discomfort - moderate40.822.48.26.114.3
Pain/discomfort - severe4.14.1004.1
Pain/discomfort - extreme00000
Anxiety/depression - none44.922.418.416.322.4
Anxiety/depression - slight34.722.412.210.220.4
Anxiety/depression - moderate16.312.26.108.2
Anxiety/depression - severe00006.1
Anxiety/depression - extreme00000
SecondaryChange From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS

EuroQoL Quality of Life Scale (EQ-5D) is a standardized instrument to assess health state values. The EQ-5D essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (VAS). For the visual analogue scale, participants draw a line from a box to the point on the thermometer-like scale corresponding to their health state, 0-100 (100 = Best health state). Weights are used to score the responses to the 5 domains, with scores ranging from 0 to 1 (where a score of 1 represents a perfect state). Scores for the visual analogue scale reflect the position where participant's line crosses the thermometer-like scale. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations

Time frame:
Baseline 12,24,36,48 weeks
Reported as:
Mean · units on a scale
Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS
units on a scaleWeek 12Week 24Week 36Week 48
Change From Baseline in EuroQoL 5-dimension Visual Analogue Scores - FAS-7.9 ± 18.98-6.1 ± 12.47-6.3 ± 10.03-11.6 ± 22.58

Adverse events

Collected over Adverse Events (AEs) are collected from the First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus + Exemestane—22/49 (44.9%)49/49 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventEverolimus + Exemestane
Lower respiratory tract infectionInfections and infestations4/49
Confusional statePsychiatric disorders3/49
AnaemiaBlood and lymphatic system disorders2/49
VomitingGastrointestinal disorders2/49
HypercalcaemiaMetabolism and nutrition disorders2/49
HyperglycaemiaMetabolism and nutrition disorders2/49
Spinal cord compressionNervous system disorders2/49
Renal failureRenal and urinary disorders2/49
PneumonitisRespiratory, thoracic and mediastinal disorders2/49
Pericardial effusionCardiac disorders1/49
Most frequent other events
Showing 10 of 48
Most frequent other events
EventEverolimus + Exemestane
DiarrhoeaGastrointestinal disorders22/49
FatigueGeneral disorders22/49
CoughRespiratory, thoracic and mediastinal disorders18/49
RashSkin and subcutaneous tissue disorders18/49
Mucosal inflammationGeneral disorders17/49
Decreased appetiteMetabolism and nutrition disorders16/49
NauseaGastrointestinal disorders14/49
Mouth ulcerationGastrointestinal disorders11/49
DyspnoeaRespiratory, thoracic and mediastinal disorders11/49
AnaemiaBlood and lymphatic system disorders8/49

Baseline characteristics

FAS

Age, Continuous
Age, Continuous(years)Everolimus and Exemestane
Mean61.3 ± 8.71
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus and Exemestane
Female49
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus and Exemestane
Caucasian48
Other1
Weight
Weight(kg)Everolimus and Exemestane
Mean71.1 ± 15.44
08

Study locations

11 sites
  • Novartis Investigative Site
    Epping, Essex CM16 6TN, United Kingdom
  • Novartis Investigative Site
    Inverness, Invernesshire IV2 3RE, United Kingdom
  • Novartis Investigative Site
    Ipswich, Suffolk IP4 5PD, United Kingdom
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Cardiff, CF14 2TL, United Kingdom
  • Novartis Investigative Site
    Denbighshire, LL18 5UJ, United Kingdom
  • Novartis Investigative Site
    East Kilbride, G75 8RG, United Kingdom
  • Novartis Investigative Site
    East Yorkshire, HU16 5JQ, United Kingdom
  • Novartis Investigative Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novartis Investigative Site
    London, SW3 6JJ, United Kingdom
  • Novartis Investigative Site
    Portsmouth, PO6 3LY, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Aug 2016, 42 months.

Results were first posted in Apr 2019, 2 years 7 months after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Dec 6, 2012
StartActual
Jan 31, 2013
Primary completionActual
Aug 15, 2016
CompletionActual
Aug 15, 2016
Results first posted
Apr 1, 2019
Last update
Jul 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01743560
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Jan 31, 2013
Primary completion
Aug 15, 2016
Completion
Aug 15, 2016
Results posted
Apr 1, 2019
Last update
Jul 18, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion